JP2022531980A5 - - Google Patents

Info

Publication number
JP2022531980A5
JP2022531980A5 JP2021567974A JP2021567974A JP2022531980A5 JP 2022531980 A5 JP2022531980 A5 JP 2022531980A5 JP 2021567974 A JP2021567974 A JP 2021567974A JP 2021567974 A JP2021567974 A JP 2021567974A JP 2022531980 A5 JP2022531980 A5 JP 2022531980A5
Authority
JP
Japan
Prior art keywords
egfr
seq
cancer
approximately
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021567974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531980A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
Publication of JP2022531980A publication Critical patent/JP2022531980A/ja
Publication of JP2022531980A5 publication Critical patent/JP2022531980A5/ja
Priority to JP2025060710A priority Critical patent/JP2025118606A/ja
Pending legal-status Critical Current

Links

JP2021567974A 2019-05-14 2020-05-14 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 Pending JP2022531980A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060710A JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
US62/847,605 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060710A Division JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Publications (2)

Publication Number Publication Date
JP2022531980A JP2022531980A (ja) 2022-07-12
JP2022531980A5 true JP2022531980A5 (enExample) 2023-07-11

Family

ID=78716450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567974A Pending JP2022531980A (ja) 2019-05-14 2020-05-14 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法
JP2025060710A Pending JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060710A Pending JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Country Status (12)

Country Link
EP (1) EP3968985A4 (enExample)
JP (2) JP2022531980A (enExample)
KR (1) KR20220010731A (enExample)
CN (1) CN113840601A (enExample)
AU (1) AU2020275272A1 (enExample)
BR (1) BR112021022828A2 (enExample)
CA (1) CA3140360A1 (enExample)
EA (1) EA202193117A1 (enExample)
IL (1) IL287962A (enExample)
MA (1) MA55978A (enExample)
MX (1) MX2021013955A (enExample)
SG (1) SG11202112412QA (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117460714A (zh) * 2021-04-30 2024-01-26 希望之城 用于癌症治疗的pcna抑制剂和egfr抑制剂
AU2024346227A1 (en) * 2023-09-21 2026-04-09 Beijing Neox Biotech Limited Multi-specific antibodies and uses thereof
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途
CN120271706A (zh) * 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
SG188802A1 (en) * 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.

Similar Documents

Publication Publication Date Title
JP2024153659A5 (enExample)
US20250064967A1 (en) Combination of antibody-drug conjugate and atr inhibitor
JP6066421B2 (ja) 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法
JP2022521610A5 (enExample)
JP2024102215A5 (enExample)
WO2019096194A1 (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN111527103A (zh) 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
TWI685341B (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2016505537A5 (enExample)
US20210346383A1 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
CN103533961A (zh) 以表皮生长因子受体为靶向的治疗癌症的组合方法
JP2007501238A (ja) 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用
US20110033453A1 (en) Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
JP2021520406A5 (enExample)
US20250262214A1 (en) Intermittent dosing regimen for azenosertib in treating cancer
JP2023539589A5 (enExample)
JP2020114849A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2023553532A5 (enExample)
TW202329936A (zh) 抗體-藥物結合物與parp1選擇性抑制劑之組合
WO2025103377A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
CN112168961A (zh) 治疗结直肠癌的联用药物组合物
JP2024521696A5 (enExample)
CN116568306A (zh) 用于治疗实体瘤的包含krasg12c抑制剂和egfr抑制剂的方法和组合物
JP2024509920A5 (enExample)